MARKET

MRUS

MRUS

Merus
NASDAQ
24.74
+1.16
+4.92%
After Hours: 24.74 0 0.00% 16:24 11/30 EST
OPEN
23.87
PREV CLOSE
23.58
HIGH
25.56
LOW
23.74
VOLUME
781.81K
TURNOVER
0
52 WEEK HIGH
27.70
52 WEEK LOW
12.44
MARKET CAP
1.43B
P/E (TTM)
-6.6547
1D
5D
1M
3M
1Y
5Y
AbbVie-Immunogen deal lifts ADC-focused biotechs
Abbvie agreed to acquire cancer drugmaker immunogen for $10.1b in cash. Immunogen is a developer of a new class of cancer drugs called antibody-drug conjugates. The deal lifts the shares of smaller adc-focused biotechs.
Seeking Alpha · 11h ago
Analysts’ Top Healthcare Picks: Merus (MRUS), Regeneron (REGN)
2 analysts have maintained buy ratings on merus and regeneron. Canaccord genuity's william maughan and jefferies' john newman are bullish on the healthcare sector. Merus has an analyst consensus of strong buy and a price target of $43.75.
TipRanks · 2d ago
Expert Ratings for Merus
These 4 analysts have an average price target of $43.0 versus the current price of merus at $24.21. Merus has observed the following analyst ratings within the last quarter. The greater the number of bullish ratings, the more positive analysts are on the stock.
Benzinga · 2d ago
Analysts Offer Insights on Healthcare Companies: Merus (MRUS) and Outlook Therapeutics (OTLK)
2 analysts have reiterated buy ratings on merus (mrus) and outlook therapeutics (otlk) h.c. Wainwright analyst andrew fein reiterated a buy rating on the healthcare sector stock merus today. Douglas tsao reiterated a buy rating on outlooktherapeutics today.
TipRanks · 2d ago
Buy Rating on Merus Stock Backed by Strong Clinical Data and Strategic Development Moves
TipRanks · 2d ago
Needham Reiterates Buy on Merus, Maintains $42 Price Target
Benzinga · 2d ago
Merus’s MCLA-129: Promising Early Results and Strategic Positioning Underpin Buy Rating
TipRanks · 3d ago
Analysts Offer Insights on Healthcare Companies: Merus (MRUS), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and BeiGene (BGNE)
TipRanks · 3d ago
More
About MRUS
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.

Webull offers Merus NV stock information, including NASDAQ: MRUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRUS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MRUS stock methods without spending real money on the virtual paper trading platform.